{"id":34774,"date":"2018-08-24T11:36:35","date_gmt":"2018-08-24T11:36:35","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=34774"},"modified":"2018-08-24T15:48:28","modified_gmt":"2018-08-24T15:48:28","slug":"fda-approved-compounds-that-might-selective-reverse-hiv-latency","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/34774","title":{"rendered":"FDA-approved compounds that might selectively reverse HIV latency"},"content":{"rendered":"<p class=\"HTBsubhead3authorcredit\"><strong><span lang=\"EN-US\"><img loading=\"lazy\" decoding=\"async\" class=\"alignright size-medium wp-image-34425\" src=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2018\/06\/LOGO-IAS-2018-combined-164x300.png\" alt=\"\" width=\"164\" height=\"300\" srcset=\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2018\/06\/LOGO-IAS-2018-combined-164x300.png 164w, https:\/\/i-base.info\/htb\/wp-content\/uploads\/2018\/06\/LOGO-IAS-2018-combined.png 188w\" sizes=\"auto, (max-width: 164px) 100vw, 164px\" \/>Simon Collins, HIV i-Base<\/span><\/strong><\/p>\n<p class=\"HTBBODYtext\"><b><span lang=\"EN-US\">A late-breaker poster from researchers at UCSF in collaboration with Merck reported optimistic news that a selection of already FDA-approved small molecule compounds selectively activate latently infected cells in vitro. <\/span><\/b><\/p>\n<p class=\"HTBBODYtext\"><span lang=\"EN-US\">The level of activity from some compounds was greater than romidepsin (the HDAC-inhibitor that has been previously used in human studies). The new compounds include <\/span>sorafenib, sunitinib, <span lang=\"EN-US\">axitinib, cabozantinib, regorafenib and carfilzomib that target new pathways (inhibiting<\/span>\u00a0VEGF, RAF-1, B-RAF and the proteosome). Importantly, <span lang=\"EN-US\">they did not show global activation of uninfected cells, also shown\u00a0<\/span>in vitro in CD4 cells from HIV positive people on supressed ART.<\/p>\n<p class=\"HTBBODYtext\">Previously studied compounds have generated broad CD4 cell activation, but at too low a level to be able to show clinical impact in reducing the viral reservoir.<\/p>\n<p class=\"HTBBODYtext\">Unfortunately only limited information is available from the study abstract and the poster is not yet available to download from the conference website.<\/p>\n<p class=\"HTBreference-noindent\"><span lang=\"EN-US\">Ref: Munoz-Arias I et al. FDA-approved chemotherapeutic drugs that inhibit VEGF, RAF-1, B-RAF and the proteosome reverse HIV latency without global T cell activation.\u00a0<\/span><span lang=\"EN-US\">AIDS 2018, 23-27 July 2018, Amsterdam. Late-breaker poster <\/span><span lang=\"EN-US\">LBPEA006.<br \/>\n<\/span><a href=\"http:\/\/programme.aids2018.org\/Abstract\/Abstract\/13445\">http:\/\/programme.aids2018.org\/Abstract\/Abstract\/13445<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base A late-breaker poster from researchers at UCSF in collaboration with Merck reported optimistic news that a selection of already FDA-approved small molecule compounds selectively activate latently infected cells in vitro. The level of activity from some &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,20],"tags":[255],"class_list":["post-34774","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-cure-research","tag-world-aids-22-amsterdam-2018"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/34774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=34774"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/34774\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=34774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=34774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=34774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}